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decreased to2 or fracture occurrence (“Delayed ZOL”). After 60months, Upfront
ZOL increased both BMD and disease-free survival (P.05) relative to Delayed ZOL.
The present analysis assessed the cost effectiveness of Upfront vs. Delayed ZOL in
this population, fromGerman (DE) and Italian (IT) payer perspectives.METHODS:A
Markov state-transition model was constructed to estimate the lifetime costs and
QALY for hypothetical cohorts of pmBCa women receiving Letrozole with Upfront
or Delayed ZOL. Consistent with ZO-FAST, at baseline, patients were 57 years old
and BCa-recurrence free. Patients could progress over time to “Local Recurrence”,
“Contralateral Tumor”, “Distant Recurrence”, or Death. Annual transition probabil-
ities were derived from ZO-FAST, supplemented with literature estimates. Direct
costs and utilitieswere literature-based. All resultswere discounted using country-
specific rates. RESULTS: In IT, Upfront ZOL treatment was associated with 15.01
QALYs and €21 998. Delayed ZOLwas associated with 13.98 QALYs and €19 458. Thus,
Upfront ZOL cost €2 453/QALY. In DE, Upfront ZOL treatment resulted in 15.44 QALYs
and €24 032. Delayed ZOL was associated with 14.37 QALYs and €23 081. Therefore,
Upfront ZOL cost €888/QALY. In both countries, the results were very insensitive to
changes in individual model input values. Compared to Delayed ZOL, Upfront ZOL
treatment cost€20000/QALY in95%of 1000probabilistic sensitivity analysismodel
runs in both IT and DE. CONCLUSIONS: This analysis suggests that treatment with
Upfront ZOLmay reduce recurrence and increase QALY and is highly cost effective
relative to a Delayed ZOL strategy from an IT and DE health care perspective.
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TREATMENT IN POST-HERCEPTIN PROGRESSION IN COLOMBIA
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OBJECTIVES: Breast Cancer (BC) is the first cause of death among women, and it
progresses to metastatic breast cancer (MBC) in half of the cases. HER-2 overex-
pression is a marker of the worst prognosis and the target of guided therapies. The
aim of this study is to assess the cost-effectiveness of therapies against BC with
overexpressed HER-2 in Colombia. METHODS: A cost-effectiveness study of MBC
treatment in HER-2-positive patients progressing to Trastuzumab was conducted,
with a 5-year horizon. Lapatinib  Capecitabine was compared to Herceptin 
chemotherapy (Capecitabine, Vinorelbine or a Taxane). The effectiveness rates of
those therapies were identified based on published primary studies. In the absence
of head-to-head comparisons, Weibull functions for each chemotherapy were es-
timated from the survival curves and were multiplied by their hazard ratios. The
perspective was that of the third payer including all direct medical costs based on
Standard National Tariffs. Finally, a Markov model was developed, incremental
cost-effectiveness ratios, (ICER), sensitivity analysis, and acceptability curve were
estimated. The discount rate used was 3%. RESULTS: Lapatinib  Capecitabine
(LC) is the most effective and less expensive alternative. Hence, it overcomes the
alternatives. The cost-effectiveness ratio of such strategy is Col$49 725 045 per year
of life gained. CONCLUSIONS: The strategy with lapatinib is cost-effective in the
treatment of MBC after progression to Herceptin.
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OBJECTIVES: The objective of this study was to estimate the cost-effectiveness of
Aromatase Inhibitors (AIs) (anastrozole, letrozole and exemastane) and tamoxifen
as adjuvant treatment of postmenopausal women with hormone receptor positive
early breast cancer. METHODS: A Markov model comprising of five health states
(on treatment, local recurrence, distant cancer, die due to breast cancer and die due
to other causes) was developed to estimate the incremental cost per quality ad-
justed life-year (QALY) gained for anastrozole, letrozole, exemestane and tamox-
ifen. The analysis was carried out from a third party payer perspective. Transition
probabilitieswere estimated based on randomized clinical trials. Drug costs, health
utilities, and direct and indirect costs were obtained from published literature. The
timehorizonusedwas 25 years for the hypothetical cohort of 1000 postmenopausal
women with hormone receptor positive breast cancer. Costs and QALY were dis-
counted by 5% annually. Sensitivity analyseswere performed by varying the values
of key parameters, QALY and costs. RESULTS: Under base case assumptions, more
QALYs per patient would be gained with letrozole (4.6) than with anastrozole (3.6),
exemestane (3.6) and tamoxifen (3.3). The cost of gaining one QALY with letrozole
was $42,307 compared with exemestane ($71,081), tamoxifen ($76,826) and anas-
trozole ($ 78,114). The estimated ICER of letrozole, exemestane and anastrozole
compared with tamoxifen was -$47,560, $9,828 and $93,513 respectively. These
resultswere robust to the two-way sensitivity analyses performed.CONCLUSIONS:
In our analysis, letrozole was the cost-effective treatment compared to anastro-
zole, exemestane and tamoxifen for the primary adjuvant treatment postmeno-
pausal women with hormone receptor positive early-stage breast cancer. Instead
of comparing only monotherapy for cost-effectiveness, future research should
consider combination therapy while allowing switching between drugs.
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OBJECTIVES: To develop a cost-effectiveness analysis based on PFS of pazopanib
versus sunitinib in the treatment of aRCC in the Mexican context.METHODS: First
an adjusted indirect comparison was calculated between pazopanib versus inter-
feron (IFN) and pazopanib versus sunitinib. The hazard ratio (HR) of pazopanib
versus BSCwas obtained from the IRC subanalysis based on scan dates for patients
who progressed; same for sunitinib versus IFN. The HR of IFN versus BSC was
obtained from the MRCRCC study. A Markov model comparing pazopanib versus
sunitinib was designed with a two years time horizon and with a 5% discount in
costs and effectiveness. The costs of drugs and adverse events (AE) grades III and IV
were included for both alternatives.We did a probabilistic sensitivity analysis (PFS)
with 1,000 simulations. Exchange rate: 1USD  13.6MXN. RESULTS: The adjusted
indirect comparison yield a HR for pazopanib versus IFN of 0.545(95% CI, 0.341-
0.871) and for pazopanib vs. sunitinib of 1.012(95% CI, 0.613-1.670). The cost-effec-
tiveness analysis showed a reduction in average cost per patient of $8171 and a
reduction of 1.15 days PFSwhenusing pazopanib compared to sunitinib; incremen-
tal cost-effectiveness ratio (ICER) of $2,525,515 per PFS year (Mexican threshold is
$13,900). According to the PSA 0.7% cases were more effective at a higher cost,
47.4% cases were more effective at a lower cost and 51.9% cases were less effective
at a lower cost comparedwith sunitinib. TheAEs cost analysis showed that the cost
of treating AEs of sunitinib was $982(95% CI, $788-$1,112) and for pazopanib was
$137(95% CI, $87-$192). CONCLUSIONS: Based on PFS time pazopanib demon-
strated to be an equivalent alternative to sunitinib in the treatment of aRCC.
Sunitinib had an ICER considerably above the Mexican threshold. Pazopanib
showed a different toxicity profile that was considerably less costly compared to
sunitinib.
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HSCT is used as the treatment of hematologic malignancies and BuCy2 is a condi-
tioning regimen before HSCT but is associated to high rates of hepatic veno-occlu-
sive disease (HVOD) mainly due to busulfan (oralBu) plasma concentration vari-
ability after oral administration. Intravenous busulfan (IVBu) shows constant
plasma concentration allowing better targeting of plasma exposure and reducing
occurrence of HVOD. OBJECTIVES: Develop an economic model based in Mexican
Institute of Social Security (IMSS) resource payments to evaluate the cost-effective-
ness of oralBu versus IVBu as conditioning regimen before HSCT in Mexico.
METHODS: A two branch decision tree model in patients with 40 or 60 kg of weight
was developed to evaluate the cost-effectiveness in Mexican pesos (MxP) of IVBu
(0.8mg/Kg/6hrs) or OralBu (1mg/Kg/6hrs) combined with intravenous cyclophos-
phamide (60mg/kg/tid) as conditioning regimen before HSCT. The effectiveness
measure was HVOD non-occurrence obtained from published clinical trials. Re-
source use and costwere obtained froman expert panel survey and IMSS published
data. The model estimated non discounted cost per patient and incremental cost-
effectiveness ratios. Probabilistic sensitivity analysis was performed using Monte
Carlo simulation second-order approach and deterministic analysis. RESULTS:
HVOD non-occurrence was 84.88% in IVBu group and 51.34% in oralBu group. Cost
per patient was lower with IVBu ($148,712.19 - $180,562.79 MxP) than OralBu
($291,088.60 to $293,296.88 MxP) showing that IVBu was the dominant alternative.
Sensitivity analysis showed model robustness and confirm IVBu as dominant.
CONCLUSIONS: IVBu is a cost-effective conditioning regimen inMexico and should
be considered by clinicians and decision makers as a favorable option before Allo-
geneic HSCT.
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OBJECTIVES: To evaluate cost-effectiveness of abiraterone and cabazitaxel com-
pared to existing palliative chemotherapy, mitoxantrone and placebo for meta-
static castration-resistant prostate cancer (mCRPC) patients; focusing on differ-
ences in baseline illness severity. METHODS: A decision tree comparing four
treatment strategies in mCRPC patients over an 18-month-period was constructed
from the societal perspective. Chance nodes included baseline pain as a severity
indicator, grade III & IV neutropenia or cardiac events, and survival at 18 months.
Probabilities and life expectancies were from two clinical trials (COU-AA1 and
TROPIC2). Costs in 2010 US dollars included drugs (Redbook), physician visits, pro-
cedures, tests (CPT-codes) and hospitalizations (HCUP). Model cost inputs included
drugs, chemotherapy administration, adverse events management, radiotherapy
for pain palliation, and death. The short duration excluded need for discounting.
Utilities for bone pain, neutropenia, cardiac events and radiation therapy were
from published sources. Baseline severity was altered to reflect relatively ill
populations. RESULTS: Cabazitaxel and abiraterone give the best effects and caba-
zitaxel ismost costly. Formitoxantrone as comparedwith placebo, the incremental
cost effectiveness ratio (ICER) was $110K/QALYS and $63K/LYS. For abiraterone
versus mitoxantrone, the ICER was $76K/QALYS and $52K/LYS. Cabazitaxel has an
ICER of $925K/QALYS and $378K/LYS compared to abiraterone. One-way and prob-
abilistic sensitivity analyses show a robust model for most variables. This re-
mained so across the majority of WTP thresholds shown in acceptability curves
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